PTGS2 and cancer: Clinically, COX-2 overexpression is associated with increased recurrence risk, shortened overall survival, and resistance to chemotherapeutic and radiotherapeutic interventions, solidifying its role as a pivotal oncogenic driver across diverse cancer types.